Clinical Trials Browser

Withdrawn × Erlotinib Hydrochloride × Clear all

NCT06161558 2025-07-16

Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors

Phase 1 Withdrawn

Neoplasms

NCT01332279 2023-04-04

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

Phase 1 Withdrawn

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT00728000 2019-11-25

Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT03529084 2019-11-22

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02689336 2019-09-09

Erlotinib in Combination With Temozolomide in Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors

Phase 2 Withdrawn

CNSGenitourinarySarcoma

Ependymoma, Glioma, Medulloblastoma, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors

NCT02355431 2019-03-08

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Phase 2 Withdrawn

Other hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Hematologic Neoplasms

NCT00428194 2017-11-29

Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer

Phase 1 Withdrawn

Uterine Cervical Neoplasms

NCT02795884 2016-12-30

Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation

Phase 3 Withdrawn

Lung Neoplasms

NCT02277457 2016-06-24

Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations

Phase EARLY_PHASE1 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT01928160 2015-07-13

Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT00934076 2015-05-08

Tarceva and AT-101 for Patients With Advanced Non-Small Cell Lung Cancer

Phase 1 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT01465815 2014-11-19

Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)

Phase 1/2 Withdrawn

Skin Neoplasms

NCT02034097 2014-05-19

A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02044601 2014-04-24

Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)

Phase 1/2 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00385398 2013-09-02

QOL-Stereotactic RadioSurgery, Temozolomide + Erlotinib-Rx of 1-3 Brain Metastases in NSCLC

Phase 2 Withdrawn

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT01728181 2013-07-25

A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation

Phase 1/2 Withdrawn

Carcinoma, Non-Small-Cell Lung, Disease

NCT01600807 2013-06-26

OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas

Phase 1/2 Withdrawn

Gastrointestinal

Adenocarcinoma, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT01013506 2013-05-23

Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT01432119 2013-04-09

Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib

Phase 1 Withdrawn

Advanced Cancers

NCT00738335 2012-10-04

Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases

Phase 1 Withdrawn

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT00293436 2012-09-17

Celecoxib and Erlotinib in Treating Patients With Liver Cancer

Phase 1/2 Withdrawn

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00754104 2011-01-19

Study of ABT-869 in Combination With Tarceva in Subjects With Solid Tumors

Phase 1 Withdrawn

Other solid neoplasm

Solid Tumors